The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1605
ISSUE 1605
August 24, 2020
Phexxi - A Nonhormonal Contraceptive Gel
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
August 24, 2020 (Issue: 1605)
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Phexxi - A Nonhormonal Contraceptive Gel
Article code: 1605a
Electronic, downloadable article - $45
Article code: 1605a
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
